Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
16
TGA:16
Drug Approvals
VOYDEYA 50 + 100 mg film-coated tablets, composite bottle pack (416091)
- Product Name
- VOYDEYA 50 + 100 mg film-coated tablets, composite bottle pack
- Approval Date
- Nov 25, 2024
TGA
VOYDEYA 50 + 100 mg film-coated tablets, composite blister pack (416092)
- Product Name
- VOYDEYA 50 + 100 mg film-coated tablets, composite blister pack
- Approval Date
- Nov 25, 2024
TGA
VOYDEYA danicopan 100 mg film-coated tablets, bottle (416090)
- Product Name
- VOYDEYA danicopan 100 mg film-coated tablets, bottle
- Approval Date
- Nov 25, 2024
TGA
VOYDEYA danicopan 100 mg film-coated tablets, blister pack (416093)
- Product Name
- VOYDEYA danicopan 100 mg film-coated tablets, blister pack
- Approval Date
- Nov 25, 2024
TGA
KOSELUGO selumetinib 25 mg capsule bottle (345972)
- Product Name
- KOSELUGO selumetinib 25 mg capsule bottle
- Approval Date
- Dec 2, 2021
TGA
KOSELUGO selumetinib 10 mg capsule bottle (345973)
- Product Name
- KOSELUGO selumetinib 10 mg capsule bottle
- Approval Date
- Dec 2, 2021
TGA
ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial (330566)
- Product Name
- ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial
- Approval Date
- Mar 23, 2021
TGA
ULTOMIRIS ravulizumab rch 1100 mg in 11 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial (336710)
- Product Name
- ULTOMIRIS ravulizumab rch 1100 mg in 11 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial
- Approval Date
- Mar 23, 2021
TGA
ULTOMIRIS ravulizumab rch 10 mg/mL concentrated solution for intravenous infusion vial (311926)
- Product Name
- ULTOMIRIS ravulizumab rch 10 mg/mL concentrated solution for intravenous infusion vial
- Approval Date
- Oct 17, 2019
TGA
KANUMA sebelipase alfa rce 2 mg/mL injection intravenous infusion vial (274498)
- Product Name
- KANUMA sebelipase alfa rce 2 mg/mL injection intravenous infusion vial
- Approval Date
- May 18, 2017
TGA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)No trials found
News
No news found